Henry Schein (NASDAQ:HSIC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC) from a hold rating to a buy rating in a report issued on Monday.

Other equities analysts have also recently issued reports about the company. Morgan Stanley reaffirmed an “underweight” rating and issued a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Piper Sandler lifted their target price on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a report on Friday, July 31st. BTIG Research reaffirmed a “buy” rating and set a $100.00 price objective on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Barrington Research set a $104.00 price objective on Henry Schein in a report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and an average price target of $92.93.

Henry Schein Price Performance

HSIC stock opened at $89.29 on Monday. The firm has a 50 day moving average price of $85.43 and a 200-day moving average price of $79.36. The firm has a market capitalization of $9.95 billion, a price-to-earnings ratio of 26.03, a PEG ratio of 1.70 and a beta of 0.80. Henry Schein has a 52-week low of $61.94 and a 52-week high of $92.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 4th. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.24 by $0.03. The business had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities research analysts forecast that Henry Schein will post 5.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein in the 2nd quarter worth approximately $27,000. Federated Hermes Inc. bought a new position in Henry Schein in the 4th quarter worth approximately $32,000. Los Angeles Capital Management LLC bought a new position in Henry Schein in the 4th quarter worth approximately $37,000. Finally, Trust Co. of Vermont purchased a new stake in Henry Schein during the 2nd quarter valued at approximately $42,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.